Nicholas P Restifo
Overview
Explore the profile of Nicholas P Restifo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
258
Citations
40305
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Schelker R, Fioravanti J, Mastrogiovanni F, Baldwin J, Rana N, Li P, et al.
Signal Transduct Target Ther
. 2024 Aug;
9(1):199.
PMID: 39117617
High frequencies of stem-like memory T cells in infusion products correlate with superior patient outcomes across multiple T cell therapy trials. Herein, we analyzed a published CRISPR activation screening to...
3.
Restifo N, Gattinoni L
J Exp Med
. 2024 Apr;
221(5).
PMID: 38634804
The creation of synthetic T cell states has captivated the field of cell-based therapies. Wang et al. (https://doi.org/10.1084/jem.20232368) describe how disruption of BCOR and ZC3H12A unleashes anti-tumor T cells with...
4.
Islam S, Maeda T, Tamaoki N, Good M, Kishton R, Paria B, et al.
Cancer Res Commun
. 2023 Jun;
3(5):917-932.
PMID: 37377887
Significance: Reprogramming of TIL into iPSC holds great promise for the future treatment of cancer due to their rejuvenated nature and the retention of tumor-specific TCRs. One limitation is the...
5.
Tamaoki N, Siebert S, Maeda T, Ha N, Good M, Huang Y, et al.
Cell Rep Methods
. 2023 May;
3(4):100460.
PMID: 37159663
Although the differentiation of human induced pluripotent stem cells (hiPSCs) into various types of blood cells has been well established, approaches for clinical-scale production of multipotent hematopoietic progenitor cells (HPCs)...
6.
Palmer D, Webber B, Patel Y, Johnson M, Kariya C, Lahr W, et al.
Med
. 2022 Aug;
3(10):682-704.e8.
PMID: 36007524
Background: Adoptive transfer of tumor-infiltrating lymphocytes (TIL) fails to consistently elicit tumor rejection. Manipulation of intrinsic factors that inhibit T cell effector function and neoantigen recognition may therefore improve TIL...
7.
8.
Kishton R, Patel S, Decker A, Vodnala S, Cam M, Yamamoto T, et al.
Cell Rep
. 2022 Aug;
40(5):111153.
PMID: 35926468
Adoptive T cell therapies (ACT) have been curative for a limited number of cancer patients. The sensitization of cancer cells to T cell killing may expand the benefit of these...
9.
Kishton R, Vodnala S, Vizcardo R, Restifo N
Curr Opin Immunol
. 2021 Oct;
74:39-45.
PMID: 34710751
The administration of T cells as cellular therapy against advanced cancers has brought clinical benefit to many patients and has progressed the field of cancer research. However, current cell therapy...
10.
Mo F, Yu Z, Li P, Oh J, Spolski R, Zhao L, et al.
Nature
. 2021 Sep;
597(7877):544-548.
PMID: 34526724
Adoptive transfer of antigen-specific T cells represents a major advance in cancer immunotherapy, with robust clinical outcomes in some patients. Both the number of transferred T cells and their differentiation...